Skip to content
Business

Novartis Adds $4bn to Three Drug Forecasts, Yet Shares Slide on a Softer 5% Growth Goal

Novartis shares fell 2.7% on 19 November after it set a 5% a year sales growth goal for 2026 to 2031, the low end of its old 5% to 6% range, despite $4bn of upgrades to three drug forecasts.

The domed Novartis Pavillon below Novartis office buildings on the Novartis Campus in Basel, May 2022
Photo: MBxd1 / Wikimedia Commons, CC BY-SA 4.0

Novartis shares fell 2.7% on Thursday 19 November after the Swiss drugmaker set a goal of 5% a year sales growth from 2026 to 2031, the bottom of the 5% to 6% range it promised a year ago. The trimmed target outweighed $4bn of upgrades to the peak-sales forecasts for three of its fastest-growing medicines and a pledge to lift its core operating margin back above 40% by 2029.

Novartis investor day in numbers

  • 5% a year sales growth target at constant currencies, 2026 to 2031
  • $18bn combined peak sales now forecast for Kesimpta, Scemblix and Leqvio, up from $14bn
  • CHF 127.94 share price after a 2.7% fall at Thursday's open

What Novartis promised investors in London

The new targets came out on Thursday in Basel, ahead of the annual Meet Novartis Management event in London. Net sales are expected to grow 5% a year at constant currencies, a measure that strips out exchange-rate swings. The core operating income margin, the share of sales left as operating profit before one-off items, is "on track to return to 40%+ by 2029", the company said.

On paper the change is small. A year ago Novartis guided to 5% to 6% annual growth for 2025 to 2030, according to a Reuters report carried by cash.ch. The window has moved on by a year and the top of the range has gone.

For 2026 itself, management confirmed its forecast of sales growth in the low single digits, with core operating income flat or up by a low single-digit percentage, cash.ch reported.

Novartis: share price, chart and news

The curved glass Frank Gehry building on the Novartis Campus in Basel, Switzerland, August 2024.
The curved glass Frank Gehry building on the Novartis Campus in Basel, Switzerland, August 2024. Photo: Alexandre Prevot / Wikimedia Commons, CC BY-SA 4.0

Why Novartis shares fell despite higher drug forecasts

The shares dropped 2.7% at the open to CHF 127.94, cash.ch reported, and dpa-AFX listed Novartis as the weakest stock in Switzerland's blue-chip SMI index. At 16:15 CET cash.ch's live quote still showed them down 2.6%, at CHF 128.06.

They fell from a height. Novartis closed at a record CHF 135.76 on Monday, and the stock is still up about 16% this year. That recovery followed its worst day on record in September, when del-desiran, a drug from its $12bn takeover of Avidity Biosciences, failed a late-stage trial and the heart drug pelacarsen also disappointed. At times the setbacks wiped almost $30bn off the company's market value, Reuters reported, and they led to a $1.9bn writedown in its third-quarter results in October.

Portfolio manager Daniel Bolanowski said the selloff reflected an "absence of anything revolutionary" in the update, according to PharmExec. Zürcher Kantonalbank noted that the new sales goal still sits above the consensus, which PharmExec put at about 4.5% a year, but said the higher product targets offered little upside. Its analyst Urban Fritsche called Novartis a "show me" story that depends on good trial data.

Kesimpta, Scemblix and Leqvio get bigger sales targets

Peak sales are the most a medicine is expected to earn in its best year. Novartis lifted that figure for three drugs:

DrugUsed forOld peak sales goalNew peak sales goal
KesimptaMultiple sclerosis$6bn$8bn
ScemblixChronic myeloid leukaemia$4bn$5bn
LeqvioLowering cholesterol$4bn$5bn

Chief executive Vas Narasimhan gave the reasons, dpa-AFX reported. Kesimpta is winning market share outside the US and still growing at home. Scemblix can now be used as a first treatment in the US. Leqvio, a cholesterol injection, is seeing strong demand in the US and Asia, above all in China and Japan.

The pill Rhapsido, also known as remibrutinib, had already had its target raised to $8bn across two forms of chronic hives and relapsing multiple sclerosis, the disease in which it beat a rival drug in two late-stage trials. Novartis now counts nine medicines on sale, Kisqali and Cosentyx among them, with peak-sales potential of $3bn to $10bn each.

How patent expiries shape the Novartis outlook

The shadow over all this is loss of exclusivity: patents run out and cheaper copies arrive. "In 2026 we expect to grow through the largest loss-of-exclusivity impact in our history," Narasimhan said in the company's statement.

The heart failure drug Entresto, the leukaemia drug Tasigna and the blood platelet drug Promacta are the main blockbusters affected, dpa-AFX reported. Entresto alone is expected to lose roughly $4bn of sales this year, according to PharmExec.

The next cliff explains the trimmed target. Narasimhan pointed to the expected expiry of the US patent on the breast cancer drug Kisqali in the second half of 2031, after which Novartis expects growing competition from copies, dpa-AFX reported.

What comes next for Novartis and its pipeline

Novartis expects more than 35 trial readouts through 2031 that could support filings for approval, and ten late-stage candidates carry multibillion-dollar peak-sales guidance. Among the drugs highlighted in London were the myelofibrosis treatment pelabresib, the lupus candidate ianalumab and two muscular dystrophy drugs from the Avidity deal, del-brax and del-zota.

"Most of the growth beyond 2031 will come from internally developed medicines," Narasimhan said at the event, PharmExec reported. The plan assumes no large acquisitions; the focus stays on deals and licences worth less than $2bn, according to dpa-AFX. Jefferies analyst Michael Leuchten said the upgrades noticeably strengthened the growth outlook, but that the presentation left open how likely the newer drugs are to succeed.

Investors showed similar doubts at Novo Nordisk's capital markets day in September, when long-term blockbuster targets also failed to lift the shares. For Novartis, the next test is data: each late-stage readout will show whether 5% is a floor or a ceiling.

Why did Novartis shares fall today?

Novartis shares fell 2.7% at the open on Thursday 19 November 2026 after the company set a target of 5% annual sales growth for 2026 to 2031, the low end of its previous 5% to 6% goal.

What is Novartis's sales growth target to 2031?

Novartis expects net sales to grow 5% a year at constant currencies from 2026 to 2031.

Which Novartis drugs are losing patent protection?

Entresto, Tasigna and Promacta are the main blockbusters losing exclusivity, and Novartis expects the US patent on Kisqali to expire in the second half of 2031, according to chief executive Vas Narasimhan.

Sources

Related stories

The Novartis logo on the white Banting 1 building on the Novartis Campus in Basel, with trees and older campus buildings below a blue sky.
Markets

Novartis Raises Its Profit Outlook Despite a $1.9bn Writedown on Del-desiran

Novartis raised its 2026 profit guidance as Q3 core operating income rose 10% to $6.04bn, beating the $5.51bn expected, even as a $1.9bn del-desiran writedown cut reported profit…

Aerial view across the Rhine from Kleinbasel to the Novartis Campus in Basel at sunset, with the round Novartis Pavillon in a riverside park.
Markets

Novartis Sinks 13.5% on Twin Trial Failures as Brent Breaks $100 and the ECB Hikes

Novartis fell 13.54% in the week to 11 September after two late-stage trial failures, while Brent jumped 8.65% to $104.61 a barrel and the ECB raised rates for the second time this…

A Novartis production specialist works at steel vessels in the RNA therapy manufacturing plant at Schweizerhalle, Switzerland (3000 x 2000)
Markets

Novartis Suffers Its Worst Day on Record, Down 10.9%, After Two Late-Stage Trial Failures

Novartis fell 10.89% to CHF 111.80 on 8 September, its worst day on record, after del-desiran, the lead drug from its $12bn Avidity deal, missed its main goal, days after…

Line chart of Soitec daily closing prices in the three months to 19 November 2026
Markets

European Stocks Fall for a Fifth Day as Soitec Jumps 12% on AI Data Centre Demand

European stocks closed lower for a fifth day on Thursday 19 November as the STOXX 600 fell 0.8%, while Soitec jumped 12% on a forecast of about 40% revenue growth from AI data…

PayPal's headquarters building at 2211 North First Street in San Jose, California, photographed in July 2013
Business

PayPal Remakes Its Top Team in One Day and Hires Xero's Claire Bramley as Finance Chief

PayPal has hired Xero finance chief Claire Bramley as CFO from 1 February 2027, succeeding Jamie Miller, and named new heads for Venmo and crypto as its chief risk officer leaves.

Main entrance of FDA Building 1 on the agency's campus in Silver Spring, Maryland, in early morning light
Business

Capricor Sinks 78% After Hours as the FDA Rejects Its Duchenne Therapy a Second Time

The FDA rejected Capricor's Duchenne cell therapy deramiocel for a second time on 20 November, citing serious data integrity problems in the HOPE-3 trial. The shares fell 78% after…

Bayer's white pipe bridge reading Science For A Better Life spanning a road in Leverkusen, Germany, April 2015
Business

Bayer's $7.25bn Roundup Settlement Wins Final Approval, Covering Cancers Not Yet Diagnosed

A St. Louis judge gave final approval on 20 November to Bayer's $7.25bn Roundup settlement, paid over up to 21 years, with average awards of $10,000 to $165,000 for cancer…

Line chart of Fireweed Metals daily closing prices in the three months to 21 November 2026
Business

Fireweed Metals Wins Up to C$14m for Mactung, Close to What It Paid for the Whole Deposit

Natural Resources Canada will put up to C$14m into Fireweed Metals' Mactung tungsten project in the Yukon for engineering and test work, but no build cost or start date was given.